Stem cells from human exfoliated deciduous teeth (SHED) and their derivatives have emerged as promising therapeutic agents for treating immune-mediated inflammatory diseases (IMIDs). IMIDs are characterized by dysregulated immune responses, leading to chronic inflammation and tissue damage. The current treatment landscape for IMIDs faces challenges, including the complexity of disease mechanisms and the limitations of existing therapies, which frequently fail to achieve long-term remission and are often associated with significant side effects. Consequently, there is a pressing need for innovative therapies that not only alleviate symptoms but also address the underlying immune dysfunction and promote the repair of damaged tissues. In this context, SHED and their derivatives offer a dual therapeutic advantage by harnessing both immunomodulatory and regenerative capacities. Research highlighted in this review demonstrates the therapeutic potential of SHED and their derivatives in multiple IMIDs, such as systemic lupus erythematosus, Sjögren's syndrome, multiple sclerosis, and rheumatoid arthritis. Critically, the aim of this review is not only to synthesize recent progress in SHED research for IMID treatment but also to highlight the strategic significance of innovative therapies emerging from the intersection of regenerative medicine and immunology.
Cui et al. (Sun,) studied this question.